CD206 macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis.
Fiche publication
Date publication
juillet 2024
Journal
Thorax
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Dr GONCALVES Victor, Dr COLLIN Bertrand, Dr BELLAYE Pierre-Simon, Pr BONNIAUD Philippe, Mr PERNET Nicolas, Dr BELTRAMO Guillaume, Dr DIAS Alexandre
Tous les auteurs :
Pommerolle L, Beltramo G, Biziorek L, Truchi M, Dias AMM, Dondaine L, Tanguy J, Pernet N, Goncalves V, Bouchard A, Monterrat M, Savary G, Pottier N, Ask K, Kolb MRJ, Mari B, Garrido C, Collin B, Bonniaud P, Burgy O, Goirand F, Bellaye PS
Lien Pubmed
Résumé
Interstitial lung diseases (ILDs) include a large number of diseases associated with progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF). Despite the rarity of each of the fibrotic ILDs individually, they cumulatively affect a considerable number of patients. PPF is characterised by an excessive collagen deposition leading to functional decline.
Mots clés
Idiopathic pulmonary fibrosis, Imaging/CT MRI etc, Interstitial Fibrosis, Macrophage Biology
Référence
Thorax. 2024 07 20;: